Analysis of prior aspirin treatment on in-hospital outcome of geriatric COVID-19 infected patients Articles uri icon

authors

  • ZEKRI NECHAR, KHAOULA
  • BARBERAN, JOSE
  • ZAMORANO LEON, JOSE J.
  • DURBAN REGUERA, MARIA LUZ
  • ANDRES CASTILLO, ALCIRA
  • NAVARRO CUELLAR, CARLOS
  • LOPEZ FARRE, ANTONIO
  • LOPEZ DE ANDRES, ANA
  • JIMENEZ GARCIA, RODRIGO
  • MARTINEZ MARTINEZ, CARLOS H.

publication date

  • November 2022

start page

  • 1

end page

  • 9

issue

  • 11, 1649

volume

  • 58

International Standard Serial Number (ISSN)

  • 1010-660X

Electronic International Standard Serial Number (EISSN)

  • 1648-9144

abstract

  • Background and Objectives: Aspirin (ASA) is a commonly used antithrombotic drug that has been demonstrated to reduce venous thromboembolism. The aim was to analyze if geriatric COVID-19 patients undergoing a 100 mg/day Aspirin (ASA) treatment prior to hospitalization differ in hospital outcome compared to patients without previous ASA therapy. Materials and Methods: An observational retrospective study was carried out using an anonymized database including geriatric COVID-19 patients (March to April 2020) admitted to Madrid Hospitals Group. A group of COVID-19 patients were treated with low ASA (100 mg/day) prior to COVID-19 infection. Results: Geriatric ASA-treated patients were older (mean age over 70 years; n = 41), had higher frequency of hypertension and hyperlipidemia, and upon admission had higher D-dimer levels than non-ASA-treated patients (mean age over 73 years; n = 160). However, patients under ASA treatment did not show more frequent pulmonary thromboembolism (PE) than non-ASA-treated patients. ASA-treated geriatric COVID-19-infected patients in-hospital less than 30 days all-cause mortality was more frequent than in non-ASA-treated COVID-19 patients. In ASA-treated COVID-19-infected geriatric patients, anticoagulant therapy with low molecular weight heparin (LMWH) significantly reduced need of ICU care, but tended to increase in-hospital less than 30 days all-cause mortality. Conclusions: Prior treatment with a low dose of ASA in COVID-19-infected geriatric patients increased frequency of in-hospital less than 30 days all-cause mortality, although it seemed to not increase PE frequency despite D-dimer levels upon admission being higher than in non-ASA users. In ASA-treated geriatric COVID-19-infected patients, addition of LMWH therapy reduced frequency of ICU care, but tended to increase in-hospital less than 30 days all-cause mortality.

subjects

  • Medicine
  • Statistics

keywords

  • aspirin; covid-19; elderly population; hospital stay; low molecular weight heparin; mortality; pulmonary thromboembolism